Translating the anti-myeloma activity of Natural Killer cells into clinical application

Cinzia Fionda, Helena Stabile, Rosa Molfetta, Alessandra Soriani, Giovanni Bernardini, Alessandra Zingoni, Angela Gismondi, Rossella Paolini, Marco Cippitelli, Angela Santoni

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Natural Killer cells (NK) are innate effector cells with a critical role in immunosurveillance against different kinds of cancer cells, including Multiple Myeloma (MM). However, the number and/or function of these lymphocytes are strongly reduced during MM progression and in advanced clinical stages. A better understanding of the mechanisms controlling both MM and NK cell biology have greatly contributed to develop novel and combined therapeutic strategies in the treatment of this incurable hematologic malignancy. These include approaches to reverse the immunosuppressive MM microenvironment or potentiate the natural or antibody-dependent cellular cytotoxicity (ADCC) of NK cells. Moreover, chemotherapeutic drugs or specific monoclonal antibodies (mAbs) can render cancer cells more susceptible to NK cell-mediated recognition and lysis; direct enhancement of NK cell function can be obtained by means of immunomodulatory drugs, cytokines and blocking mAbs targeting NK cell inhibitory receptors. Finally, adoptive transfer of ex-vivo expanded and genetically manipulated NK cells is also a promising therapeutic tool for MM. Here, we review current knowledge on complex mechanisms affecting NK cell activity during MM progression. We also discuss recent advances on innovative approaches aimed at boosting the functions of these cytotoxic innate lymphocytes. In particular, we focus our attention on recent preclinical and clinical studies addressing the therapeutic potential of different NK cell-based strategies for the management of MM.

Original languageEnglish
Pages (from-to)255-264
Number of pages10
JournalCancer Treatment Reviews
Volume70
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Natural Killer Cells
Multiple Myeloma
Monoclonal Antibodies
Lymphocytes
Immunologic Monitoring
Blocking Antibodies
Adoptive Transfer
Hematologic Neoplasms
Therapeutics
Immunosuppressive Agents
Pharmaceutical Preparations
Cell Biology
Neoplasms
Cytokines
Antibodies

Keywords

  • Immunotherapy
  • Multiple myeloma
  • NK cells

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Translating the anti-myeloma activity of Natural Killer cells into clinical application. / Fionda, Cinzia; Stabile, Helena; Molfetta, Rosa; Soriani, Alessandra; Bernardini, Giovanni; Zingoni, Alessandra; Gismondi, Angela; Paolini, Rossella; Cippitelli, Marco; Santoni, Angela.

In: Cancer Treatment Reviews, Vol. 70, 01.11.2018, p. 255-264.

Research output: Contribution to journalReview article

Fionda, C, Stabile, H, Molfetta, R, Soriani, A, Bernardini, G, Zingoni, A, Gismondi, A, Paolini, R, Cippitelli, M & Santoni, A 2018, 'Translating the anti-myeloma activity of Natural Killer cells into clinical application', Cancer Treatment Reviews, vol. 70, pp. 255-264. https://doi.org/10.1016/j.ctrv.2018.10.005
Fionda, Cinzia ; Stabile, Helena ; Molfetta, Rosa ; Soriani, Alessandra ; Bernardini, Giovanni ; Zingoni, Alessandra ; Gismondi, Angela ; Paolini, Rossella ; Cippitelli, Marco ; Santoni, Angela. / Translating the anti-myeloma activity of Natural Killer cells into clinical application. In: Cancer Treatment Reviews. 2018 ; Vol. 70. pp. 255-264.
@article{925a0ed1f08148ecae35d413a6175095,
title = "Translating the anti-myeloma activity of Natural Killer cells into clinical application",
abstract = "Natural Killer cells (NK) are innate effector cells with a critical role in immunosurveillance against different kinds of cancer cells, including Multiple Myeloma (MM). However, the number and/or function of these lymphocytes are strongly reduced during MM progression and in advanced clinical stages. A better understanding of the mechanisms controlling both MM and NK cell biology have greatly contributed to develop novel and combined therapeutic strategies in the treatment of this incurable hematologic malignancy. These include approaches to reverse the immunosuppressive MM microenvironment or potentiate the natural or antibody-dependent cellular cytotoxicity (ADCC) of NK cells. Moreover, chemotherapeutic drugs or specific monoclonal antibodies (mAbs) can render cancer cells more susceptible to NK cell-mediated recognition and lysis; direct enhancement of NK cell function can be obtained by means of immunomodulatory drugs, cytokines and blocking mAbs targeting NK cell inhibitory receptors. Finally, adoptive transfer of ex-vivo expanded and genetically manipulated NK cells is also a promising therapeutic tool for MM. Here, we review current knowledge on complex mechanisms affecting NK cell activity during MM progression. We also discuss recent advances on innovative approaches aimed at boosting the functions of these cytotoxic innate lymphocytes. In particular, we focus our attention on recent preclinical and clinical studies addressing the therapeutic potential of different NK cell-based strategies for the management of MM.",
keywords = "Immunotherapy, Multiple myeloma, NK cells",
author = "Cinzia Fionda and Helena Stabile and Rosa Molfetta and Alessandra Soriani and Giovanni Bernardini and Alessandra Zingoni and Angela Gismondi and Rossella Paolini and Marco Cippitelli and Angela Santoni",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2018.10.005",
language = "English",
volume = "70",
pages = "255--264",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Translating the anti-myeloma activity of Natural Killer cells into clinical application

AU - Fionda, Cinzia

AU - Stabile, Helena

AU - Molfetta, Rosa

AU - Soriani, Alessandra

AU - Bernardini, Giovanni

AU - Zingoni, Alessandra

AU - Gismondi, Angela

AU - Paolini, Rossella

AU - Cippitelli, Marco

AU - Santoni, Angela

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Natural Killer cells (NK) are innate effector cells with a critical role in immunosurveillance against different kinds of cancer cells, including Multiple Myeloma (MM). However, the number and/or function of these lymphocytes are strongly reduced during MM progression and in advanced clinical stages. A better understanding of the mechanisms controlling both MM and NK cell biology have greatly contributed to develop novel and combined therapeutic strategies in the treatment of this incurable hematologic malignancy. These include approaches to reverse the immunosuppressive MM microenvironment or potentiate the natural or antibody-dependent cellular cytotoxicity (ADCC) of NK cells. Moreover, chemotherapeutic drugs or specific monoclonal antibodies (mAbs) can render cancer cells more susceptible to NK cell-mediated recognition and lysis; direct enhancement of NK cell function can be obtained by means of immunomodulatory drugs, cytokines and blocking mAbs targeting NK cell inhibitory receptors. Finally, adoptive transfer of ex-vivo expanded and genetically manipulated NK cells is also a promising therapeutic tool for MM. Here, we review current knowledge on complex mechanisms affecting NK cell activity during MM progression. We also discuss recent advances on innovative approaches aimed at boosting the functions of these cytotoxic innate lymphocytes. In particular, we focus our attention on recent preclinical and clinical studies addressing the therapeutic potential of different NK cell-based strategies for the management of MM.

AB - Natural Killer cells (NK) are innate effector cells with a critical role in immunosurveillance against different kinds of cancer cells, including Multiple Myeloma (MM). However, the number and/or function of these lymphocytes are strongly reduced during MM progression and in advanced clinical stages. A better understanding of the mechanisms controlling both MM and NK cell biology have greatly contributed to develop novel and combined therapeutic strategies in the treatment of this incurable hematologic malignancy. These include approaches to reverse the immunosuppressive MM microenvironment or potentiate the natural or antibody-dependent cellular cytotoxicity (ADCC) of NK cells. Moreover, chemotherapeutic drugs or specific monoclonal antibodies (mAbs) can render cancer cells more susceptible to NK cell-mediated recognition and lysis; direct enhancement of NK cell function can be obtained by means of immunomodulatory drugs, cytokines and blocking mAbs targeting NK cell inhibitory receptors. Finally, adoptive transfer of ex-vivo expanded and genetically manipulated NK cells is also a promising therapeutic tool for MM. Here, we review current knowledge on complex mechanisms affecting NK cell activity during MM progression. We also discuss recent advances on innovative approaches aimed at boosting the functions of these cytotoxic innate lymphocytes. In particular, we focus our attention on recent preclinical and clinical studies addressing the therapeutic potential of different NK cell-based strategies for the management of MM.

KW - Immunotherapy

KW - Multiple myeloma

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=85054654749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054654749&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.10.005

DO - 10.1016/j.ctrv.2018.10.005

M3 - Review article

VL - 70

SP - 255

EP - 264

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -